focus -WSS

focus

author：hotspot 2025-09-29 01:07:05 - browse：149

The Food and Drug Administration is poised to tell drug and medical device makers how to better include people of color in the clinical trials that test whether products work and are safe, an agency official said Wednesday. Those guidelines are five months late.

To ensure that drugs work for everyone, they must be tested on a representative sample of people. But researchers have found that many clinical trials exclude the people of color who are often most affected by the diseases that drugs treat.

To help fix that problem, Congress passed a law requiring companies to give the FDA their plans for diversifying clinical trials. As part of that process, the agency was expected to issue guidance by the end of last year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Medicaid rebukes states for mistakenly disenrolling children

WSS

A new House health package & hospitals’ new site

The (many) problems with a new study criticizing cancer screening

Even great ERs can’t make up for American health disparities

How generative AI is inspiring dreams of a health data revolution

Quicker fix for pulse oximeters urged during FDA public meeting

New Ultima Genomics DNA sequencer can read genome for $100

knowledge

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

hotspot

Medical records are filled with copy

FDA drug safety: Singulair case shows systemic surveillance flaws

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Advances in CAR

Heart attack and stroke risk calculators need revising

Vertex non

How to save PrEP access — and even expand it

Biden administration opens offers in Medicare drug price negotiations

Trump demands the U.S. pay no more for drugs than other countries … again

Even great ERs can’t make up for American health disparities

entertainment

How to protect patients from sexual assault

NIH nominee Bertagnolli will get October confirmation hearing

Advances in CAR

The (many) problems with a new study criticizing cancer screening

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

How to fix cancer clinical trials' diversity problem

hotspot

explore

Wikipedia

hotspot